Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
about
Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewOverexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim inductionMolecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaOutcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemiaClinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patientsComparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspensionLow expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiaClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsPrognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.Perspectives of proteomics in acute myeloid leukemia.
P2860
Q26772235-D30AE0D6-C599-4E81-B477-BFDFAA20D37DQ27851545-56519DED-4DD2-4F38-975A-34E3FDA41473Q28301344-1DA69FAD-E479-44AF-A23F-02217390B956Q28482247-EEAECE91-E687-471A-96A2-6AF6EA526432Q30252938-F0DD0772-31EE-4F1D-B8E4-50AD40CAFB21Q30497200-89D9175D-3851-49D7-B5CD-DC335083FE92Q30620658-BC9FE25A-92F0-4D20-8522-80DE1C33A95DQ33264716-52D73F0D-8996-442D-9AE0-1F80250AB8E8Q33380148-362C9D8D-B264-4C39-9405-3ABCC77A8560Q33412609-4FB1AB9A-BE81-4631-A5FA-0A5A1438310CQ33555627-59565FB4-D969-41AB-B757-B3B5A955E11EQ33558780-9439A79F-8128-4089-BD0C-B31820E2E3AFQ33680186-BDF83C8C-52D2-4239-B51D-96AF9ADEBB5DQ33841988-C2A9E164-2171-448A-B0B0-0144D2006209Q33917204-F7D4DFFE-00AE-40E1-A68C-B1B9925C2D1AQ33968372-B48BE254-49B4-41DD-B3CB-D602F28E0AB4Q34018590-54FE87D7-6FD5-4A14-A902-DAFED71E2EF2Q34022803-BD5FCF47-2EEC-4E6C-8AD3-A901337A01E3Q34060237-4C633334-E808-44D3-BFED-C285C72F79F0Q34162844-2072B322-9A35-432F-BE40-3D5F5515A6FCQ34276134-968AB8BB-B92D-4DB8-B84D-4F2721D45B33Q34524753-F0379519-EB33-4575-9D6B-750AFC6C1DD1Q34541748-47164BE9-D2BB-4822-8A79-01626252F735Q34597777-F6DCC9E6-DCC4-4D4E-8E27-62F9F20F9109Q34630588-07D1917A-FBE8-4F31-A3E8-A26AE32DE09BQ34631111-A840F309-CF72-4D8C-8967-BA05220A30BCQ34663691-87397254-F7F9-485B-A4FA-BBCEB008AF3FQ34766817-3B42DE2C-558A-4462-B107-EFF48DB8C4B0Q34831106-20C28C6F-84CB-454B-8145-4706D9DD75A5Q35125889-25E650CF-86B1-4827-BC4E-E8750C9E5EC7Q35256120-DACD3725-B692-4BA0-BAD7-DF93FCCBBC19Q35794120-00C8F6FA-7965-4AC2-93B3-0143E44C3C7DQ35800831-FE8C35DF-B4FA-4104-BD9B-35B18BAD7354Q35922032-AD42A15E-3D70-4793-9C90-61E7440D870BQ36057877-1B5D6013-7F02-4598-9EF4-197EB244B8A9Q36219674-B740997E-B866-41AB-926E-A2AC7D4AEF19Q36400942-D7310116-FE24-4646-BE6A-08B6AD032B1BQ36457184-B5BA9B94-D9BE-46E5-9E2B-68D3DD39C483Q36498399-95E7A334-1376-494D-BB8F-5E0D277B8F46Q36668271-424D2240-C52C-4570-AB56-BBF47421077E
P2860
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pretreatment cytogenetics add ...... cer and Leukemia Group B 8461.
@ast
Pretreatment cytogenetics add ...... cer and Leukemia Group B 8461.
@en
type
label
Pretreatment cytogenetics add ...... cer and Leukemia Group B 8461.
@ast
Pretreatment cytogenetics add ...... cer and Leukemia Group B 8461.
@en
prefLabel
Pretreatment cytogenetics add ...... cer and Leukemia Group B 8461.
@ast
Pretreatment cytogenetics add ...... cer and Leukemia Group B 8461.
@en
P2093
P2860
P50
P1433
P1476
Pretreatment cytogenetics add ...... ncer and Leukemia Group B 8461
@en
P2093
Amy S Ruppert
Andrew J Carroll
Cancer and Leukemia Group B 8461
Clara D Bloomfield
James W Vardiman
Krzysztof Mrózek
Maria R Baer
Mark J Pettenati
Prasad R Koduru
Richard M Stone
P2860
P356
10.1182/BLOOD-2005-11-4354
P407
P577
2006-03-07T00:00:00Z